This systematic review compared the efficacy of injectable versus transdermal testosterone inincreasing lean body mass (LBM) in adult men with hypogonadism over 12 weeks. An analysisof five studies, including clinical trials, revealed that both formulations significantly increaseLBM. However, injectable testosterone (enanthate/cypionate) demonstrated potentially greaterpotency and superior absolute gains, attributed to its supraphysiological serum peaks. Incontrast, transdermal testosterone (gel) provided a more predictable, dose-dependent, and stableincrease in LBM, with a favorable tolerability profile despite the risk of skin irritation. Theevidence suggests that injectable testosterone may be more effective for maximizing muscleanabolism in the short term, while the transdermal route offers superior hormonal stability.Therefore, the choice of therapy should be individualized, balancing the goal of maximizingmuscular gains against the preference for treatment convenience and stability
Constitutional Delay of Growth and Puberty (CDGP) is the most common cause of delayed puberty and a prevalent complaint in pediatric endocrinology, often associated with short stature in adolescence. This systematic review and meta-analysis aimed to synthesize the available evidence to estimate the prevalence of CDGP in this population. Following PRISMA guidelines, searches were conducted across multiple databases with no initial date restriction. Observational studies reporting the proportion of CDGP in adolescents with short stature were included. The quantitative synthesis used a random-effects model. Ten studies, totaling 1,516 participants, met the criteria. The pooled prevalence of delayed puberty was 69.7% (95% CI: 23.8% to 94.4%). However, heterogeneity among studies was extremely high (I² = 98.5%), and the confidence interval is wide, reflecting substantial uncertainty. Subgroup analyses indicated that age range, diagnostic criteria, and, most importantly, selection bias in referral settings are the main sources of this variation. It is concluded that the reported prevalence of CDGP is highly variable and contingent on clinical context and methodological definitions, not representing a robust population estimate. Future studies with standardized criteria and more diverse populations are needed.
Introduction: Growth hormone (GH) plays a key role in metabolic adaptation to fasting by stimulating lipolysis and preserving lean mass. However, there is no consensus on the magnitude of the GH response to short-term fasting in healthy adults. Objective: To systematically review the literature on the effect of 24-48 hour fasting on GH levels in healthy adults. Methods: A search was conducted in PubMed, Google Scholar, and Science Direct (2000-2025). Original studies with healthy adults undergoing 24-48h fasting and measuring GH as an outcome were included. A narrative synthesis was performed due to study heterogeneity. Results: Six studies (n=119 participants) were included. Twenty-four-hour fasting increased GH by 3-5 fold, without IGF-1 elevation (hepatic resistance). Prolonged fasting (≥36h) intensified the response, increasing GH pulse frequency and amplitude. The GH increase was associated with decreased insulin and leptin, stimulating lipolysis. Individuals with low basal GH showed greater relative increases. Discussion: Twenty-four to forty-eight-hour fasting significantly increases GH secretion in healthy adults, with a more pronounced response during prolonged fasting and in individuals with low basal GH. The GH-IGF-1 dissociation suggests adaptive hepatic resistance.
Background: Vitamin D modulates innate and adaptive immunity and has been investigated for preventing pediatric respiratory infections. Objective: To assess the effects of vitamin D supplementation on respiratory tract infections (RTIs), including upper RTIs, lower RTIs/recurrent pneumonia, and hospitalization/clinical severity in children and adolescents. Methods: Systematic review and random-effects meta-analysis of 16 publications, of which 13 contributed to quantitative synthesis. Twenty-four effect estimates were pooled, eight per outcome. The odds ratio (OR) was analyzed on its natural logarithmic scale (logOR), using restricted maximum likelihood (REML) estimation and Knapp-Hartung (KH) adjusted inference. Where necessary, risk ratios (RRs), hazard ratios (HRs), and incidence rate ratios (IRRs) were approximated on the logOR scale. Results: For respiratory infection/upper RTI, pooled logOR was −0.284 (KH-adjusted 95% confidence interval [CI]: −0.678 to 0.110; OR 0.753; p = 0.132; I 2 = 97.2%). For lower RTI/recurrent pneumonia, logOR was −0.445 (95% CI: −0.987 to 0.097; OR 0.641; p = 0.093; I 2 = 89.5%). For hospitalization/clinical severity, logOR was −0.609 (95% CI: −1.134 to −0.083; OR 0.544; p = 0.029; I 2 = 78.3%). Conclusions: Pooled estimates favored supplementation in direction for all three groups, although confidence intervals included the null for the first two. Heterogeneity was substantial, and the results are limited by approximations among effect measures, clinically diverse endpoints, and potentially correlated effects from individual studies.